NYXH
Nyxoah S.A. NASDAQ Listed Apr 28, 2021$1.77
+2.91%
vs $1.72
Mkt Cap $70.1M
52w Low $1.26
7.0% of range
52w High $8.59
50d MA $2.44
200d MA $4.03
P/E (TTM)
-0.8x
EV/EBITDA
—
P/B
1.4x
Debt/Equity
0.9x
ROE
—
P/FCF
-1.0x
RSI (14)
81.70
ATR (14)
$0.12
Beta
0.87
50d MA
$2.44
200d MA
$4.03
Avg Volume
514.5K
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Rue Edouard Belin 12 · Mont-Saint-Guibert 1435 · BE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.65 | -0.68 | -4.6% | 3.09 | +1.3% | -0.3% | +2.6% | +0.9% | -0.6% | -2.5% | — |
| Nov 13, 2025 | AMC | -0.61 | -0.74 | -21.3% | 5.31 | -10.5% | -5.8% | -4.8% | -2.9% | -2.6% | +1.1% | — |
| Aug 18, 2025 | AMC | -0.62 | -0.63 | -1.6% | 6.57 | +2.7% | -4.6% | +1.3% | +0.0% | +1.3% | +0.5% | — |
| May 14, 2025 | AMC | -0.49 | -0.63 | -28.6% | 6.06 | +3.0% | +2.8% | +1.0% | +7.9% | +13.4% | +4.5% | — |
| Mar 13, 2025 | AMC | -0.46 | -0.49 | -6.5% | 10.05 | +9.0% | +4.6% | -1.0% | +1.8% | +4.2% | +3.8% | — |
| Nov 6, 2024 | AMC | -0.46 | -0.55 | -19.6% | 10.00 | -4.2% | -3.6% | -1.6% | -3.8% | -3.6% | -2.3% | — |
| Aug 6, 2024 | AMC | -0.45 | -0.46 | -2.2% | 7.89 | +6.5% | +4.4% | +1.2% | +2.4% | -3.6% | -2.4% | — |
| May 14, 2024 | AMC | -0.45 | -0.45 | +0.0% | 9.58 | +25.4% | +7.2% | +1.6% | -3.2% | -1.0% | +1.2% | — |
| Mar 5, 2024 | AMC | -0.41 | -0.41 | +0.0% | 15.00 | -4.9% | -8.3% | +8.2% | +7.7% | +6.1% | +2.9% | — |
| Nov 8, 2023 | AMC | -0.48 | -0.29 | +39.6% | 5.76 | -5.2% | -15.1% | -0.2% | +5.1% | -2.9% | -2.1% | — |
| Aug 8, 2023 | AMC | -0.45 | -0.49 | -8.9% | 7.72 | -1.2% | -1.2% | +3.4% | +0.1% | +1.1% | +1.1% | — |
| May 16, 2023 | AMC | -0.37 | -0.49 | -32.4% | 7.92 | -4.2% | -2.9% | +2.3% | -3.9% | -0.1% | -6.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 | Stifel | Downgrade | Buy → Hold | $5 | $3.33 | $3.21 | -3.6% | -7.8% | +0.3% | -5.2% | +5.5% | -5.2% |
| Apr 10 | Stifel | Maintains | Buy → Buy | — | $2.87 | $2.88 | +0.3% | -0.3% | +3.5% | +10.5% | +3.4% | -3.0% |
| Mar 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.08 | $3.10 | +0.6% | +2.6% | +0.9% | -0.6% | -2.5% | -8.7% |
| Mar 20 | Stifel | Maintains | Buy → Buy | — | $3.09 | $3.13 | +1.3% | -0.3% | +2.6% | +0.9% | -0.6% | -2.5% |
| Jan 29 | Stifel | Maintains | Buy → Buy | — | $4.90 | $4.92 | +0.4% | -0.2% | -2.9% | -0.4% | -2.3% | +1.1% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.31 | $4.75 | -10.5% | -5.8% | -4.8% | -2.9% | -2.6% | +1.1% |
| Apr 21 | Stifel | Maintains | Buy → Buy | — | $6.04 | $6.07 | +0.5% | -1.7% | +1.9% | -0.3% | -1.8% | -0.8% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.71 | $6.82 | +19.4% | +6.1% | +3.0% | -3.7% | +2.3% | -2.8% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.33 | $10.98 | -3.1% | -21.4% | -10.2% | -4.4% | -8.8% | -1.6% |
| Mar 14 | Stifel | Maintains | Buy → Buy | — | $10.05 | $10.95 | +9.0% | +4.6% | -1.0% | +1.8% | +4.2% | +3.8% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.88 | $8.59 | +9.0% | +1.5% | +0.0% | -0.1% | -0.6% | +0.8% |
| Nov 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.44 | $9.64 | +2.1% | +5.4% | +0.5% | -3.6% | -1.6% | -3.8% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.25 | -3.2% | +0.4% | -1.0% | +0.0% | +0.0% | +0.5% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.70 | $9.60 | -1.0% | -1.5% | -3.4% | +0.2% | -2.4% | +0.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.89 | $8.40 | +6.5% | +4.4% | +1.2% | +2.4% | -3.6% | -2.4% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.89 | $8.40 | +6.5% | +4.4% | +1.2% | +2.4% | -3.6% | -2.4% |
| Aug 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.89 | $8.40 | +6.5% | +4.4% | +1.2% | +2.4% | -3.6% | -2.4% |
| Jun 24 | Stifel | Maintains | Buy → Buy | — | $8.51 | $8.39 | -1.4% | -6.6% | +0.0% | -13.6% | +0.0% | +1.5% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.33 | $8.50 | +2.0% | +2.0% | +0.6% | +1.5% | +5.6% | +2.6% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.58 | $12.01 | +25.4% | +7.2% | +1.6% | -3.2% | -1.0% | +1.2% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.58 | $12.01 | +25.4% | +7.2% | +1.6% | -3.2% | -1.0% | +1.2% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.58 | $12.01 | +25.4% | +7.2% | +1.6% | -3.2% | -1.0% | +1.2% |
| May 15 | Stifel | Maintains | Buy → Buy | — | $9.58 | $12.01 | +25.4% | +7.2% | +1.6% | -3.2% | -1.0% | +1.2% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.72 | $15.49 | +5.2% | -7.9% | -1.4% | -0.8% | +1.7% | -9.1% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.73 | $16.06 | -4.0% | -16.9% | +7.1% | -1.1% | -7.9% | -1.4% |
| Mar 20 | Stifel | Maintains | Buy → Buy | — | $16.73 | $16.06 | -4.0% | -16.9% | +7.1% | -1.1% | -7.9% | -1.4% |
| Mar 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.13 | $17.12 | -0.1% | -3.2% | -0.2% | +17.8% | -14.2% | -16.9% |
| Mar 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.00 | $14.26 | -4.9% | -8.3% | +8.2% | +7.7% | +6.1% | +2.9% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.00 | $14.26 | -4.9% | -8.3% | +8.2% | +7.7% | +6.1% | +2.9% |
| Mar 5 | Stifel | Maintains | Buy → Buy | — | $15.83 | $15.30 | -3.3% | -5.2% | -8.3% | +8.2% | +7.7% | +6.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.35 | $14.59 | -5.0% | -8.7% | -1.6% | +7.1% | +7.1% | -5.2% |
| Jan 4 | Stifel | Maintains | Buy → Buy | — | $22.00 | $21.98 | -0.1% | +0.2% | -0.2% | -1.1% | +2.3% | +0.0% |
| Jan 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $22.00 | $21.98 | -0.1% | +0.2% | -0.2% | -1.1% | +2.3% | +0.0% |
| Jan 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.00 | $21.98 | -0.1% | +0.2% | -0.2% | -1.1% | +2.3% | +0.0% |
| Jul 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.80 | $33.50 | +2.1% | +0.6% | -1.5% | -0.2% | +1.5% | -1.5% |
| Jul 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $32.80 | $33.50 | +2.1% | +0.6% | -1.5% | -0.2% | +1.5% | -1.5% |
| Jul 27 | Stifel | Maintains | Buy → Buy | — | $32.69 | $32.26 | -1.3% | +0.3% | +0.6% | -1.5% | -0.2% | +1.5% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | BlackRock Health Sciences Opportunities Portfolio | 337,359 | $1M | Feb 2026 |
Valuation
Market Cap
$70.1M
Enterprise Value
$37.1M
P/E (TTM)
-0.83x
Forward P/E
—
PEG Ratio
-0.05x
P/B
1.37x
P/S
4.13x
P/FCF
-0.99x
EV/EBITDA
—
Shares Out
38.1M
Financials (TTM)
Revenue
$16.3M
Net Income
-$86.1M
EBITDA
-$77.2M
Free Cash Flow
-$68.3M
Op Cash Flow
-$67.5M
EPS Basic
$-2.37
EPS Diluted
$-2.14
EPS Forward
$-1.86
Gross Margin
48.3%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$118.4M
Total Liab.
$69.3M
Total Equity
$49.1M
Cash
$48.0M
LT Debt
$17.7M
Book Value/Sh
$1.29
Debt/Equity
0.86x
Current Ratio
1.25
Quick Ratio
1.16
Returns & Growth
ROE
—
ROA
—
ROIC
-90.9%
Rev Growth YoY
+121.5%
EPS Growth YoY
-30.9%
Price Returns
2W
+10.6%
1M
+22.1%
3M
-46.4%
6M
-64.7%
12M
-77.5%
Technicals
52W High
$8.59
52W Low
$1.26
50d MA
$2.44
200d MA
$4.03
RSI (14)
81.70
ATR (14)
$0.12
Beta
0.87
Avg Volume
515K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.50
High
$9.00
Low
$8.00
Median
$8.50
Data updated apr 26, 2026 4:41pm
· Source: financialmodelingprep.com